AI Article Synopsis
- A new nanoparticle vaccine targeting the receptor-binding domain (RBD) of SARS-CoV-2 has been developed to provide broad protection against various sublineages, including emerging variants.
- This vaccine induces strong neutralizing antibodies and T-cell responses, which are essential for combating respiratory infections.
- Administered intranasally, the vaccine generates significant immune responses in the nasal passages and offers potential as a universal vaccine against multiple sarbecoviruses.
Article Abstract
Because of the rapid mutation and high airborne transmission of SARS-CoV-2, a universal vaccine preventing the infection in the upper respiratory tract is particularly urgent. Here, a mosaic receptor-binding domain (RBD) nanoparticle (NP) vaccine is developed, which induces more RBD-targeted type IV neutralizing antibodies (NAbs) and exhibits broad cross-protective activity against multiple SARS-CoV-2 sublineages including the newly-emerged BF.7, BQ.1, XBB. As several T-cell-reactive epitopes, which are highly conserved in sarbecoviruses, are displayed on the NP surface, it also provokes potent and cross-reactive cellular immune responses in the respiratory tissue. Through intranasal delivery, it elicits robust mucosal immune responses and full protection without any adjuvants. Therefore, this intranasal mosaic NP vaccine can be further developed as a pan-sarbecovirus vaccine to block the viral entrance from the upper respiratory tract.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520630 | PMC |
| http://dx.doi.org/10.1002/advs.202301034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FcRn-guided antigen trafficking enhances cancer vaccine efficacy.
Cancer Immunol Immunother
January 2025
Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, People's Republic of China.
The development of tumor vaccines represents a significant focus within cancer therapeutics research. Nonetheless, the efficiency of antigen presentation in tumor vaccine remains suboptimal. We introduce an innovative mRNA-lipid nanoparticle platform designed to express tumor antigenic epitopes fused with the transmembrane domain and cytoplasmic tail of the neonatal Fc receptor (FcRn).
View Article and Find Full Text PDFmRNA-LNP vaccines combined with tPA signal sequence elicit strong protective immunity against .
mSphere
December 2024
Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, China.
is a prominent Gram-negative and encapsulated opportunistic pathogen that causes a multitude of infections such as severe respiratory and healthcare-associated infections. Despite the widespread anti-microbial resistance and the high mortality rate, currently, no clinically vaccine is approved for battling . To date, messenger RNA (mRNA) vaccine is one of the most advancing technologies and are extensively investigated for viral infection, while infrequently applied for prevention of bacterial infections.
View Article and Find Full Text PDFUnderstanding the self-assembly and molecular structure of mRNA lipid nanoparticles at real size: Insights from the ultra-large-scale simulation.
Int J Pharm
December 2024
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau 999078, China; Faculty of Health Sciences, University of Macau, Macau 999078, China. Electronic address:
Messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNPs) represents a cutting-edge delivery technology that played a pivotal role during the COVID-19 pandemic and in advancing vaccine development. However, molecular structure of mRNA-LNPs at real size remains poorly understood, with conflicting results from various experimental studies. In this study, we aim to explore the assembly process and structural characteristics of mRNA-LNPs at realistic sizes using coarse-grained molecular dynamic simulations.
View Article and Find Full Text PDFMucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling nanoparticles.
Vaccine
December 2024
Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia. Electronic address:
Recombinant influenza viruses are promising vectors that can bolster antibody and resident lymphocyte responses within mucosal sites. This study evaluates recombinant influenza viruses with SARS-CoV-2 RBD genes in eliciting mucosal and systemic responses. Using reverse genetics, we generated replication-competent recombinant influenza viruses carrying heterologous RBD genes in monomeric, trimeric, or ferritin-based nanoparticle forms.
View Article and Find Full Text PDFCritical Role of Nanomaterial Mechanical Properties in Drug Delivery, Nanovaccines and Beyond.
Adv Mater
December 2024
School of Chemical Engineering, The University of Adelaide, North Terrace, South Australia, 5005, Australia.
Nanomaterials have become essential in the daily lives, finding applications in food, skincare, drugs, and vaccines. Traditionally, the surface chemistry of nanoparticles (NPs) is considered the key factor in determining their interactions with biological systems. However, recent studies have shown that the mechanical properties of nanomaterials are equally important in regulating nano-bio interactions, though they have often been overlooked.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!